Medicine, Health & Food
Volume: 140 , Issue: 1 , January Published Date: 08 January 2024
Publisher Name: IJRP
Views: 316 , Download: 295 , Pages: 572 - 579
DOI: 10.47119/IJRP1001401120246015
Publisher Name: IJRP
Views: 316 , Download: 295 , Pages: 572 - 579
DOI: 10.47119/IJRP1001401120246015
Authors
# | Author Name |
---|---|
1 | Alyssa Mutia Mutiara |
2 | Rahmania Kemala Dewi |
3 | Pradana Zaky Romadhon |
Abstract
Background: On January 30, 2020, the 2019 coronavirus epidemic (2019-nCoV) was assessed as potentially harmful to humans by the World Health Organization (WHO). On the same date, the WHO also stated that 7,818 cases had been reported and 170 deaths had been recorded. On March 11, 2020, WHO published that the coronavirus disease outbreak was categorized as a pandemic. (WHO, 2021) The Indonesian state recorded that the first Indonesian citizen who was declared infected with COVID-19 came from Depok City on March 2, 2020 COVID-19 patients with comorbid or comorbid diseases have a higher mortality rate compared to patients without congenital diseases. One of the most common comorbidities found in COVID-19 patients is hypertension. The prevalence of COVID-19 patients with hypertension reached 56.6%.